MAP2K7 and acute myeloid leukemia: Although there is no clinical activity for MEK and AKT inhibition [40] or Ara-C and CHK1 inhibition [85], several combination therapies have shown clinical efficacy for AML treatment [30,31,32,46,47,48,72].